Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alobresib +/- Enzalutamide in mCRPC
NCT02607228Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alobresib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Gilead Sciences. Started Dec 2015; status: terminated.
02
Drugs
alobresib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02607228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607228.